Brian Choi, MD
Hematology-Oncology · Riverside, CANPI 1386602720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.9% of the total across 1,683 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 8.4% — the pattern of someone who eats at a lot of different presentations.
Across 1,683 payments — averaging $20.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- Merck$3K
- Novartis$3K
- AstraZeneca$2K
- Pfizer$2K
- E.r. Squibb & Sons, L.L.C.$1K
- plus $20K from 54 others
Across 40 payments — averaging $3520.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$59K
- Puma Biotechnology, Inc.$30K
- Array Biopharma Inc$21K
- Takeda Pharmaceuticals U.S.A., Inc.$15K
- Amgen$5K
- Sobi, Inc$5K
- plus $6K from 2 others
What the payments were for
- Food & beverage$33,63697%
- Education$1,0583%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS - Symmetry$147
- ZYNLONTA$105
How this compares
$34,694 in reported general payments places this provider in the 80th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 25 | $562,125 |
| IbrancePalbociclib | 29 | $439,964 |
| BrukinsaZanubrutinib | 37 | $403,020 |
| RevlimidLenalidomide | 15 | $291,352 |
| TabrectaCapmatinib Hydrochloride | 11 | $247,671 |
| InlytaAxitinib | 12 | $245,069 |
| XtandiEnzalutamide | 18 | $219,074 |
| LynparzaOlaparib | 12 | $203,591 |
| ImbruvicaIbrutinib | 11 | $169,850 |
| KisqaliRibociclib Succinate | 15 | $137,792 |
| RuxienceRituximab-Pvvr | 34 | $129,115 |
| LonsurfTrifluridine/Tipiracil Hcl | 11 | $106,230 |
| OrgovyxRelugolix | 31 | $80,389 |
| KanjintiTrastuzumab-Anns | 14 | $65,105 |
| TrazimeraTrastuzumab-Qyyp | 18 | $64,514 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Inlyta, Ruxience, Trazimera, Eliquis | $1,597 | $885,183104 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $1,498 | $562,12525 claims |
| Beigene USA, Inc.Brukinsa | $589 | $403,02037 claims |
| NovartisTabrecta, Kisqali | $2,561 | $385,46326 claims |
| Bristol Myers SquibbRevlimid | $1,085 | $291,35215 claims |
| Astellas Pharma US IncXtandi | $896 | $219,07418 claims |
| AstraZenecaLynparza | $2,403 | $203,59112 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $319 | $169,85011 claims |
| Taiho Oncology, Inc.Lonsurf | $184 | $106,23011 claims |
| AmgenKanjinti, Xgeva | $742 | $105,34227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in Riverside
- James BerensonWest Hollywood$1M
- Ari BaronSan Francisco$705K
- Jeffrey WolfSan Francisco$407K
- Haresh JhangianiFountain Valley$77K
- Mark ScholzMarina del Rey$62K
- Derrick SuFountain Valley$53K
- Peyman Salimi-TariFountain Valley$49K
- Janet PanFountain Valley$46K
- Bertrand TuanSan Francisco$45K
- Shawn ShambaughBakersfield$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.